Fluoxetine in the prevention of depressive recurrences: a double-blind study
- PMID: 11476126
- DOI: 10.1097/00004714-200108000-00009
Fluoxetine in the prevention of depressive recurrences: a double-blind study
Abstract
Optimal outcomes from depression treatment are long-term recovery and, in the case of recurrent depression, prevention of new episodes. However, few data are available concerning the long-term efficacy of antidepressants in prophylactic treatment to prevent recurrences of depression. The efficacy and safety of fluoxetine 20 mg/day was evaluated in reducing the number of depressive episodes and in extending the time free of symptoms in patients with recurrent unipolar major depression. Patients with recurrent unipolar major depression according to DSM-III-R criteria and who responded to 32 weeks of open-label fluoxetine were randomly assigned to receive fluoxetine 20 mg/day (N = 70) or placebo (N = 70) for 48 weeks of double-blind maintenance treatment. Outcome measures were the percentage of recurrences and time to recurrence. Safety assessments included treatment-emergent adverse events, reasons for discontinuation, vital signs, and laboratory measures. Fluoxetine was associated with a statistically significantly smaller percentage of patients who had a recurrence compared with placebo (20% vs. 40%; chi2 analysis, p = 0.010). The symptom-free period was significantly longer for patients treated with fluoxetine versus placebo (295 vs. 192 days; Kaplan-Meier estimates, log-rank test, p = 0.002). Treatments were well tolerated during maintenance treatment. The only statistically significant difference in adverse events between treatment groups was anxiety, which was more frequent in the placebo group (fluoxetine, 12.9% vs. placebo, 30%; chi2 analysis, p = 0.013). Two placebo-treated patients and no fluoxetine-treated patients were withdrawn because of adverse events. In conclusion, fluoxetine at 20 mg/day was effective and well tolerated for the prophylactic treatment of recurrent unipolar major depression.
Similar articles
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.J Clin Psychiatry. 2007 Aug;68(8):1246-56. doi: 10.4088/jcp.v68n0812. J Clin Psychiatry. 2007. PMID: 17854250 Clinical Trial.
-
"Wish bias" in antidepressant drug trials?J Clin Psychopharmacol. 2004 Apr;24(2):126-30. doi: 10.1097/01.jcp.0000115665.45074.0d. J Clin Psychopharmacol. 2004. PMID: 15206658 Review.
-
The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.J Clin Psychiatry. 2000 Nov;61(11):851-7. doi: 10.4088/jcp.v61n1107. J Clin Psychiatry. 2000. PMID: 11105738 Clinical Trial.
-
Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.J Clin Psychopharmacol. 1998 Dec;18(6):435-40. doi: 10.1097/00004714-199812000-00003. J Clin Psychopharmacol. 1998. PMID: 9864074 Clinical Trial.
-
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.J Clin Psychiatry. 1991 Aug;52(8):329-35. J Clin Psychiatry. 1991. PMID: 1907963 Clinical Trial.
Cited by
-
Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013495. doi: 10.1002/14651858.CD013495.pub2. Cochrane Database Syst Rev. 2021. PMID: 33886130 Free PMC article.
-
Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis.Mol Psychiatry. 2021 Jan;26(1):118-133. doi: 10.1038/s41380-020-0843-0. Epub 2020 Jul 23. Mol Psychiatry. 2021. PMID: 32704061 Free PMC article.
-
Prophylactic Ketamine Treatment Promotes Resilience to Chronic Stress and Accelerates Recovery: Correlation with Changes in Synaptic Plasticity in the CA3 Subregion of the Hippocampus.Int J Mol Sci. 2019 Apr 8;20(7):1726. doi: 10.3390/ijms20071726. Int J Mol Sci. 2019. PMID: 30965559 Free PMC article.
-
Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population.Curr Neuropharmacol. 2018 Mar 5;16(3):234-270. doi: 10.2174/1570159X15666170818095105. Curr Neuropharmacol. 2018. PMID: 28820053 Free PMC article. Review.
-
Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression.Sci Rep. 2017 Jan 25;7:41382. doi: 10.1038/srep41382. Sci Rep. 2017. PMID: 28120908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources